Wells Fargo & Company Increases Integra LifeSciences (NASDAQ:IART) Price Target to $15.00

Key Points

• Wells Fargo raised its price target on Integra to $15.00 (from $12.00) with an "equal weight" rating, implying roughly a 12.3% upside from the current share price.
• Q1 results beat expectations—EPS $0.54 vs. $0.41 and revenue ~$392M vs. $381.8M—and management raised FY 2026 EPS guidance to $2.40–$2.50, above Street consensus.
• Near-term caution: Q2 guidance (EPS $0.44–$0.52; revenue $410–$425M) came in slightly below Street estimates, analysts maintain a mixed stance with a consensus "Reduce" rating and the company announced a leadership transition to a new CEO.

Integra LifeSciences (NASDAQ:IART - Get Free Report) had its price objective boosted by equities research analysts at Wells Fargo & Company from $12.00 to $15.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the life sciences company's stock. Wells Fargo & Company's target price suggests a potential upside of 12.28% from the stock's current price.

IART has been the subject of a number of other reports. Wall Street Zen downgraded shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Argus reaffirmed a "hold" rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Citigroup reduced their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating for the company in a research report on Wednesday, March 11th. Finally, Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating for the company in a research report on Wednesday, April 15th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus target price of $14.80.

Integra LifeSciences Stock Up 1.1%

Shares of NASDAQ:IART traded up $0.14 during midday trading on Wednesday, hitting $13.36. 163,476 shares of the company's stock were exchanged, compared to its average volume of 809,029. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $16.49. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The stock has a 50 day moving average price of $10.11 and a 200-day moving average price of $11.73. The company has a market cap of $1.04 billion, a PE ratio of -1.98 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The business had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same period in the prior year, the firm posted $0.41 EPS. The firm's quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts anticipate that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP grew its position in shares of Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company's stock valued at $96,304,000 after acquiring an additional 100,000 shares during the period. Invesco Ltd. grew its position in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company's stock valued at $43,754,000 after acquiring an additional 31,931 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company's stock valued at $45,634,000 after acquiring an additional 267,134 shares during the period. State Street Corp grew its position in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company's stock valued at $34,933,000 after acquiring an additional 21,717 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its position in shares of Integra LifeSciences by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company's stock valued at $33,099,000 after acquiring an additional 135,198 shares during the period. 84.78% of the stock is owned by institutional investors.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — quarterly EPS of $0.54 topped consensus ~$0.41 and revenue of ~$392M exceeded estimates, showing modest growth versus year‑ago figures. Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Full‑year EPS guidance raised to $2.40–$2.50, above consensus (~$2.35), giving longer‑term earnings visibility and suggesting management expects recovery/growth later in the year. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Leadership change announced — Stuart Essig named next President & CEO and Michael McBreen appointed Chief Commercial Officer; this is material but the impact depends on execution and strategy under new leadership. Integra LifeSciences Announces Leadership Transition
• Neutral Sentiment: Investors can review management commentary and detail in the earnings call transcript and slide deck for product/segment color that could drive forward guidance revisions. Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q2 guidance came in below Street expectations — management gave Q2 EPS of $0.44–$0.52 (consensus ~$0.53) and revenue guidance $410–$425M (vs. ~$425.3M consensus), creating near‑term growth risk and the main reason for the muted/negative market reaction. Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.